Ram Kishun Verma

Dr. Ram Kishun Verma

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GDGagandeep Dhillon
Gagandeep Dhillon
VBVenkata Buddhavarapu
Venkata Buddhavarapu
HGHarpreet Grewal
Harpreet Grewal
PSPranjal Sharma
Pranjal Sharma
RVRam Kishun Verma
Ram Kishun Verma
Rahul KashyapRahul Kashyap
Rahul Kashyap
Hydrogen-rich water (HRW) has emerged as a novel approach in the field of health and wellness. It is believed to have therapeutic antioxidant properties that can neutralize harmful free radicals in the human body. It has also been shown to be beneficial in mitigating oxidative stress-induced damage through its anti-inflammatory and anti-apoptotic pathways. We aim to conduct a systematic review to evaluate the potential benefits of hydrogen-rich water. The review protocol was uploaded on PROSPERO. After the initial search criteria, the articles were reviewed by two blinded investigators, and a total of 25 articles were included in the systematic review. The potential benefits of hydrogen-rich water on various aspects of health, including exercise capacity, physical endurance, liver function, cardiovascular disease, mental health, COVID-19, oxidative stress, and anti-aging research, are a subject of growing interest and ongoing research. Although preliminary results in clinical trials and studies are encouraging, further research with larger sample sizes and rigorous methodologies is needed to substantiate these findings. Current research needs to fully explain the mechanisms behind the potential benefits of hydrogen-rich water. Continued scientific exploration will provide valuable insights into the potential of hydrogen-rich water as an adjunctive therapeutic approach in the future.

18 May 2017 in Monaldi Archives for Chest Disease
Verified
Journal Article
Open access
PDF file
ASAbhijeet Singh
Abhijeet Singh
RPRajendra Prasad
Rajendra Prasad
RGRajiv Garg
Rajiv Garg
SKSurya Kant
Surya Kant
GHGiridhar B. Hosmane
Giridhar B. Hosmane
RVRam Kishun Verma
Ram Kishun Verma
Obstructive Sleep Apnea Syndrome (OSAS) has been recognised as a major cause of morbidity and mortality in developing countries like India. There is still a paucity of Indian studies regarding the prevalence of OSAS. The current single centre prospective cross-sectional study was undertaken to know prevalence estimates for key symptoms and features that can indicate the presence of OSAS in an Indian population. A survey was conducted on subjects with age groups ≥ 25 years at King George's Medical University, Lucknow, Uttar Pradesh, India from August 2009 to July 2011. Data was recorded during the interview on the basis of Berlin Questionnaire (BQ). Risk factors for OSAS were also evaluated. Risk group categorization for OSAS was done with the help of a questionnaire and overnight polysomnography was performed in each group to measure apnea and hypopnea index (AHI). Out of 1816 subjects, 1512 (response rate 83.3%) finally participated in the survey with mean age 42.6±11.2 years, males 67.9% and females 32.1%. Of them 6.2% were found to be at high-risk OSAS; 12.2% were obese (Body Mass Index ≥30 kg/m2) and 33.5% of the obese population were at high-risk OSAS. Among high-risk patients with OSAS, 62.4% had hypertension. Statistically significant and independent risk factors found for OSAS were obesity, large neck size, alcoholism and use of sedatives/tranquillizers. High-risk category predicted an AHI ≥5 with a sensitivity of 86.3% (95% CI 73.1-93.8), specificity of 93.1% (95% CI 89.1-95.7), positive and negative predictive values of 70.9% (95% CI 57.9-81.4) and 97.2% (95% CI 94.1-98.8) respectively. It can be concluded that BQ questionnaire can still be used as a pre-assessment tool for predicting persons at risk for OSAS in clinical practice. Further studies on estimation of prevalence of OSAS by applying BQ are warranted in near future from other regions of India.

1 August 2024 in Endocrines
Verified
Journal Article
Open access
PDF file
PSPranjal Sharma
Pranjal Sharma
VBVenkata Buddhavarapu
Venkata Buddhavarapu
GDGagandeep Dhillon
Gagandeep Dhillon
RVRam Kishun Verma
Ram Kishun Verma
RDRamprakash Devadoss
Ramprakash Devadoss
Rahul KashyapRahul Kashyap
Rahul Kashyap
As obesity evolves as a global pandemic, the use of drugs to treat it is booming. The latest among these are Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Along with their use, the incidence of adverse events has become more common. Although severe effects have been mentioned, details and associations are unclear regarding some of them. We performed a systematic review of studies related to GLP-1 RA drugs. Drugs that have been the subject of at least three studies meeting all our criteria were included. Analysis of GLP-1 RA therapies across eight studies, involving 4422 subjects, indicated varying rates of Serious Adverse Events (SAEs). Semaglutide demonstrated an SAE incidence of 8.9%, compared to 6.2% for Liraglutide. These results were not statistically significant. For both drugs, no clear association with pancreatitis or neoplasm was established. Discontinuation rates due to adverse effects were 10.3% for Semaglutide and 8.3% for Liraglutide. Severe adverse effects with GLP-1 RA use are not uncommon, and warrant further close monitoring when patients are started on treatment. Further studies are required to analyze the difference between the adverse effect profiles of each drug and to assess whether or not each of these severe adverse effects is dose dependent.

Verified
Journal Article
Open access
PDF file
RDRamprakash Devadoss
Ramprakash Devadoss
GDGagandeep Dhillon
Gagandeep Dhillon
PSPranjal Sharma
Pranjal Sharma
RVRam Kishun Verma
Ram Kishun Verma
RMRipudaman Singh Munjal
Ripudaman Singh Munjal
Rahul KashyapRahul Kashyap
Rahul Kashyap
Heart failure is a cardiovascular condition, leading to fatigue, breathlessness, and fluid retention. It affects around 56 million people globally and is a leading cause of hospitalization and mortality. Its prevalence is rising due to aging populations and lifestyle factors. Managing heart failure demands a multidisciplinary approach, encompassing medications, lifestyle modifications, and often medical devices or surgeries. The treatment burden is substantial, impacting patients’ daily lives and straining healthcare systems. Improving early detection, novel therapies, and patient education are crucial for alleviating the burden and enhancing the quality of life. There are notable advancements in the field of heart failure treatment and prevention. We will discuss significant pharmacological and device advances related to heart failure, including angiotensin receptor–neprilysin inhibitor, sodium–glucose co-transporter inhibition, glucagon-like peptide-1 agonist, cardiac resynchronization therapy, cardiac contractility modulation, mechanical circulatory support devices, and transcatheter valve interventions. We will also review novel therapies on the horizon, emerging technologies like CRISPR-based treatments for genetic anomalies, and the involvement of artificial intelligence in heart failure detection and management.

26 June 2023 in Cureus
Verified
Journal Article
Open access
PDF file
RVRam Kishun Verma
Ram Kishun Verma
VPVinita Prasad
Vinita Prasad
SRSubhendu Rath
Subhendu Rath
VMVarun Monga
Varun Monga
GDGagandeep Dhillon
Gagandeep Dhillon
Observing cataplexy episodes during an office visit is extremely rare as they are usually triggered by laughter or emotional stress. Narcolepsy usually occurs in the younger population. We report a case of a 65-year-old Caucasian female with a past medical history of obesity who developed excessive daytime sleepiness, fatigue, and sleep attacks five weeks after getting influenza and pneumococcal vaccines. The presentation of cataplexy was atypical. Several episodes of cataplexy were observed during the office visit without any emotional trigger. Further workup, including polysomnography (PSG), was positive for obstructive sleep apnea, controlled with continuous positive airway pressure (CPAP) use. Later, she had PSG with CPAP use, which optimally controlled obstructive sleep apnea, followed by multiple sleep latency tests (MSLT) with CPAP use. It was positive for narcolepsy with a mean sleep latency of 1.6 minutes with sleep onset rapid eye movement (REM) in five out of five naps. Her cerebrospinal fluid (CSF) hypocretin level was extremely low at 50 pg/ml, usually seen in narcolepsy with cataplexy. She was also positive for human leukocyte antigen (HLA) DBQ1*06:02. The diagnosis of narcolepsy with cataplexy was made, which improved with medications for narcolepsy.

1 January 2024 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
PSPranjal Sharma
Pranjal Sharma
VBVenkata Buddhavarapu
Venkata Buddhavarapu
GDGagandeep Dhillon
Gagandeep Dhillon
RVRam Kishun Verma
Ram Kishun Verma
RDRamprakash Devadoss
Ramprakash Devadoss
Rahul KashyapRahul Kashyap
Rahul Kashyap
Introduction: As obesity evolves as a global pandemic along with diabetes mellitus, the development and use of drugs used to treat the same is booming. The latest among them is Glucagon-like peptide-1 receptor agonists (GLP-1 RA). Along with the use, the incidence of adverse events has become more common. It becomes imperative to focus on severe adverse effects for this reason. Although mentioned, there has been no detailed discussions regarding severe adverse effects and associations are also unclear regarding some. Methods: A systematic search was conducted for full length manuscripts published in the last two decades. We focused on papers that listed severe adverse effects with some details. Studies involving the pediatric population and patients on multiple oral antihyperglycemics were excluded. Statistical Analysis: Data analysis was performed using Revman 5.0 version. Results: The analysis of GLP-1RA therapies across 8 studies, involving 4422 subjects, indicates varying rates of Serious Adverse Events (SAE). Semaglutide demonstrates an SAE incidence of 8.9%, compared to 6.2% with Liraglutide, though not statistically significant. The analysis indicated Semaglutide had an elevated SAE risk with an Odds ratio (OR)=1.27, but did not have statistical significance (95% CI 0.84-1.91, p=0.26, I2=63%). Similarly, patients in the Liraglutide group had an increased risk of SAE with OR of 1.19 (95%CI 0.91-1.55, p=0.86, I2=40%) but this did not reach statistical significance. In both Semaglutide and Liraglutide, gastrointestinal adverse events predominate, with pancreatitis and neoplasm incidence noted, albeit without a clear causal relationship established. Discontinuation rates due to adverse effects were 10.3% for Semaglutide versus 3.1% for placebo, and 8.3% for Liraglutide versus 3.3% for placebo. The classification of these incidents as SAEs was unclear, and hence, they were excluded from statistical analysis. Conclusion: Severe adverse effects with GLP-1 RA are not uncommon and warrant further close monitoring when patients are started on the treatment. Further studies are required to analyze the difference between the adverse effect profiles of each drug and to assess whether or not each of the severe adverse effects is dose dependent.